Literature DB >> 28183041

An automated flow system incorporating in-line acid dissolution of bismuth metal from a cyclotron irradiated target assembly for use in the isolation of astatine-211.

Matthew J O'Hara1, Anthony J Krzysko2, Cynthia M Niver2, Samuel S Morrison2, Stanley L Owsley2, Donald K Hamlin3, Eric F Dorman3, D Scott Wilbur3.   

Abstract

Astatine-211 (211At) is a promising cyclotron-produced radionuclide being investigated for use in targeted alpha therapy. The wet chemical isolation of trace quantities of 211At, produced within several grams of Bi metal deposited onto an aluminum cyclotron target assembly, involves a multi-step procedure. Because the 211At isolation method is labor-intensive and complex, automation of the method is being developed to facilitate routine processing at the University of Washington and to make it easier to transfer the process to other institutions. As part of that automation effort, a module useful in the initial step of the isolation procedure, dissolution of the Bi target, was designed and tested. The computer-controlled module performs in-line dissolution of Bi metal from the target assembly using an enclosed target dissolution block, routing the resulting solubilized 211At/Bi mixture to the subsequent process step. The primary parameters involved in Bi metal solubilization (influent HNO3 concentration and flow rate) were optimized prior to evaluation of the system using replicate 211At-bearing cyclotron irradiated targets. The results indicate that the system performs in a predictable and reproducible manner, with cumulative Bi and 211At recoveries following a sigmoidal function.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Astatine-211, (211)At; Bismuth metal dissolution; Cyclotron target; Laboratory automation; Radioimmunotherapy; Targeted alpha therapy

Year:  2017        PMID: 28183041     DOI: 10.1016/j.apradiso.2017.02.001

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  4 in total

Review 1.  Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Authors:  Sture Lindegren; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Emma Aneheim
Journal:  Cancer Biother Radiopharm       Date:  2020-02-20       Impact factor: 3.099

2.  Investigation of a tellurium-packed column for isolation of astatine-211 from irradiated bismuth targets and demonstration of a semi-automated system.

Authors:  Yawen Li; Donald K Hamlin; Ming-Kuan Chyan; Taylor M Morscheck; Maryline G Ferrier; Roger Wong; D Scott Wilbur
Journal:  Sci Rep       Date:  2019-11-18       Impact factor: 4.379

Review 3.  Production, purification and availability of 211At: Near term steps towards global access.

Authors:  Yutian Feng; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2021-06-10       Impact factor: 2.947

4.  Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets.

Authors:  Matthew J O'Hara; Anthony J Krzysko; Donald K Hamlin; Yawen Li; Eric F Dorman; D Scott Wilbur
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.